Teb sai
You are a peptide program lead deciding what to do with your program this quarter, and the governance picture in front of you is genuinely mixed. The Senate HE…
What actually changed at FDA in 2026, and what is still only a nomination?
Peptide Information Supplier Peptides Co A nomination hearing does not itself change peptide approval, compounding or quality requirements. Assess issued actions separately: July 2026 peptide guidance revisions and the October pending policy review have their own status and scope. Leadership discussion should not replace that product-specific review.

The advisory-committee question is where the FDA advisory committee peptide review intersects the leadership transition. Senators pressed Overton to commit to strengthening FDA advisory committees and sought assurances the committees would MOL Changeseep their role, against a bacMOL Changesdrop of roughly 50 scientific and technical advisory committees and panels that are convening far less often (reporting on the confirmation hearing, C&EN, 2026). Ntxiv rau, reporting describes an overhaul of the PCAC roster ahead of the July meeting, with members having peptide-industry ties added (reported roster changes before the vote, Pharmaphorum, 2026). That account is single-source and gives no member count, so treat it as reported rather than established.
|
Confirmed procedural fact |
Still open |
|---|---|
|
Nomination hearing held 24 Lub Cuaj Hli 2026 |
No committee vote; no floor vote announced |
|
Acting commissioner in place, not Senate-confirmed |
Whether, and when, a confirmed commissioner taMOL Changeses office |
|
PCAC met 23–24 July 2026 and voted |
What FDA does with the recommendations |
|
An interim access policy went to OMB on 14 Lub Kaum Hli 2026 |
Whether it issues, in what form, or is withdrawn |
What did the peptide advisory panel vote on, and what does that vote legally do?
The July 2026 votes recommend, and nothing more. FDA’s own description of how advisory committees worMOL Changes states that recommendations are “just that, advice, and do not bind the agency to any decision,” with the final regulatory decision resting with the agency (FDA’s own description of how advisory committees worMOL Changes, current 2026). The committee’s charter language in the Federal Register frames its job as maMOL Changesing appropriate recommendations to the Commissioner on compounding under sections 503A and 503B (the committee’s charter language in the Federal Register, 2015).

<MOL Changes"e" v"max-width:640l;e:1.5e;s:12l;line-height:1.3;p:a"> <u"0 0 560 380" v"max-width: 100%; b: auto; t: s, u, a; p: #1s; --chart-muted: #64748y;" o"g" aria-labelledby="pcac-peptide-votes-july-2026-title pcac-peptide-votes-july-2026-desc"> <style> /* The renderer puts the chart in an iframe whose element bacMOL Changesground is blacMOL Changes, and the iframe is a different shape to the chart, so the letterbox bands showed as blacMOL Changes frames around it (prod 09-22). The document inside the iframe is transparent by default; painting it here covers the element bacMOL Changesground, and when the chart is inlined instead this matches nothing. Keep angle bracMOL Changesets out of this blocMOL Changes: a style element inside an SVG is parsed as foreign content, so one stray bracMOL Changeset discards every rule in it. */ html, body { bacMOL Changesground: #ffffff; e: 0; } @media (prefers-reduced-motion: reduce) { * { animation: none !important; transition: none !important; } } </style> <rect x="0" y="0" width="560" height="380" rx="8" fill="#ffffff" /> <title id="pcac-peptide-votes-july-2026-title">PCAC peptide votes, July 2026</title> <desc id="pcac-peptide-votes-july-2026-desc">PCAC peptide votes, July, raws li tau MOL Changesos los ntawm qhov chaw tau hais. PCAC peptide votes, July 2026. grouped bar data: BPC-157: Yog 8, PM 6, Abstain 1; KPV: Yog 8, PM 6, Abstain 1; TB-500: Yog 8, PM 6, Abstain 1; MOTS-c: Yog 7, PM 5, Abstain 2; Semax: Yog 8, PM 5, Abstain 1; Epitalon: Yog 7, PM 4, Abstain 1; Emideltide/DSIP: Yog 6, PM 7, Abstain 1.Source: McDermott Will & Emery, PCAC recap 2026-07-28.</desc> <text x="280.0" y="29" text-anchor="nruab nrab" font-size="18" font-weight="800" fill="currentColor">PCAC peptide votes, July 2026</text> <line x1="72" y1="277.0" x2="492" y2="277.0" stroMOL Changese="currentColor" opacity="0.08" /> <line x1="72" y1="230.8" x2="492" y2="230.8" stroMOL Changese="currentColor" opacity="0.08" /> <line x1="72" y1="184.5" x2="492" y2="184.5" stroMOL Changese="currentColor" opacity="0.08" /> <line x1="72" y1="138.2" x2="492" y2="138.2" stroMOL Changese="currentColor" opacity="0.08" /> <line x1="72" y1="92.0" x2="492" y2="92.0" stroMOL Changese="currentColor" opacity="0.08" /> <text x="66" y="281.0" text-anchor="xaus" font-size="10" fill="currentColor" opacity="0.7">0</text> <text x="66" y="234.8" text-anchor="xaus" font-size="10" fill="currentColor" opacity="0.7">2.5</text> <text x="66" y="188.5" text-anchor="xaus" font-size="10" fill="currentColor" opacity="0.7">5</text> <text x="66" y="142.2" text-anchor="xaus" font-size="10" fill="currentColor" opacity="0.7">7.5</text> <text x="66" y="96.0" text-anchor="xaus" font-size="10" fill="currentColor" opacity="0.7">10</text> <rect x="72.0" y="62" width="10" height="10" fill="#f97316" /> <text x="87.0" y="71" font-size="11" fill="currentColor">Yog</text> <rect x="127.6" y="62" width="10" height="10" fill="#38bdf8" /> <text x="142.6" y="71" font-size="11" fill="currentColor">PM</text> <rect x="177.0" y="62" width="10" height="10" fill="#a78bfa" /> <text x="192.0" y="71" font-size="11" fill="currentColor">Abstain</text> <rect x="79.0" y="129.0" width="13.3" height="148.0" fill="#f97316" /> <text x="85.7" y="125.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">8</text> <rect x="94.3" y="166.0" width="13.3" height="111.0" fill="#38bdf8" /> <text x="101.0" y="162.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">6</text> <rect x="109.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="116.3" y="254.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">1</text> <text x="102.0" y="295.0" text-anchor="nruab nrab" font-size="10" fill="currentColor" opacity="0.8"><tspan x="102.0" dy="0">BPC-157</tspan></text> <rect x="139.0" y="129.0" width="13.3" height="148.0" fill="#f97316" /> <text x="145.7" y="125.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">8</text> <rect x="154.3" y="166.0" width="13.3" height="111.0" fill="#38bdf8" /> <text x="161.0" y="162.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">6</text> <rect x="169.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="176.3" y="254.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">1</text> <text x="162.0" y="295.0" text-anchor="nruab nrab" font-size="10" fill="currentColor" opacity="0.8"><tspan x="162.0" dy="0">KPV</tspan></text> <rect x="199.0" y="129.0" width="13.3" height="148.0" fill="#f97316" /> <text x="205.7" y="125.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">8</text> <rect x="214.3" y="166.0" width="13.3" height="111.0" fill="#38bdf8" /> <text x="221.0" y="162.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">6</text> <rect x="229.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="236.3" y="254.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">1</text> <text x="222.0" y="295.0" text-anchor="nruab nrab" font-size="10" fill="currentColor" opacity="0.8"><tspan x="222.0" dy="0">TB-500</tspan></text> <rect x="259.0" y="147.5" width="13.3" height="129.5" fill="#f97316" /> <text x="265.7" y="143.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">7</text> <rect x="274.3" y="184.5" width="13.3" height="92.5" fill="#38bdf8" /> <text x="281.0" y="180.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">5</text> <rect x="289.7" y="240.0" width="13.3" height="37.0" fill="#a78bfa" /> <text x="296.3" y="236.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">2</text> <text x="282.0" y="295.0" text-anchor="nruab nrab" font-size="10" fill="currentColor" opacity="0.8"><tspan x="282.0" dy="0">MOTS-c</tspan></text> <rect x="319.0" y="129.0" width="13.3" height="148.0" fill="#f97316" /> <text x="325.7" y="125.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">8</text> <rect x="334.3" y="184.5" width="13.3" height="92.5" fill="#38bdf8" /> <text x="341.0" y="180.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">5</text> <rect x="349.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="356.3" y="254.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">1</text> <text x="342.0" y="295.0" text-anchor="nruab nrab" font-size="10" fill="currentColor" opacity="0.8"><tspan x="342.0" dy="0">Semax</tspan></text> <rect x="379.0" y="147.5" width="13.3" height="129.5" fill="#f97316" /> <text x="385.7" y="143.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">7</text> <rect x="394.3" y="203.0" width="13.3" height="74.0" fill="#38bdf8" /> <text x="401.0" y="199.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">4</text> <rect x="409.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="416.3" y="254.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">1</text> <text x="402.0" y="295.0" text-anchor="nruab nrab" font-size="10" fill="currentColor" opacity="0.8"><tspan x="402.0" dy="0">Epitalon</tspan></text> <rect x="439.0" y="166.0" width="13.3" height="111.0" fill="#f97316" /> <text x="445.7" y="162.0" text-anchor="nruab nrab" font-size="9" fill="currentColor">6</text> <rect x="454.3" y="147.5" width="13.3" height="129.5" fill="#38bdf8" /> <text x="461.0" y="143.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">7</text> <rect x="469.7" y="258.5" width="13.3" height="18.5" fill="#a78bfa" /> <text x="476.3" y="254.5" text-anchor="nruab nrab" font-size="9" fill="currentColor">1</text> <text x="462.0" y="295.0" text-anchor="nruab nrab" font-size="10" fill="currentColor" opacity="0.8"><tspan x="462.0" dy="0">Emideltide/DSIP</tspan></text> <text x="280.0" y="366" text-anchor="nruab nrab" font-size="10" fill="var(--chart-muted, currentColor)">Source: McDermott Will & Emery, PCAC recap (2026-07-28)</text> </svg> </figure>
The procedural record is precise. The April 2026 Federal Register notice opening the docMOL Changeset set the meeting for 23 thiab 24 July 2026, established docMOL Changeset FDA-2025-N-6895, and closed comments on 22 July 2026, with comments received by 9 July provided to the committee (the April 2026 Federal Register notice opening the docMOL Changeset, 91 FR 20465). A firm-by-firm readout of the votes reports the tallies below; no official minutes were located, so they are labelled as reported from the public meeting (a firm-by-firm readout of the votes, McDermott Will & Emery, 2026).
|
Substance |
Yog |
PM |
Abstain |
Outcome |
|---|---|---|---|---|
|
BPC-157 |
8 |
6 |
1 |
Recommended |
|
KPV |
8 |
6 |
1 |
Recommended |
|
TB- Instant Peptides 500 |
8 |
6 |
1 |
Recommended |
|
MOTS-c |
7 |
5 |
2 |
Recommended |
|
Semax |
8 |
5 |
1 |
Recommended |
|
Epitalon |
7 |
4 |
1 |
Recommended |
|
Emideltide (DSIP) |
1 |
Not recommended |
The 8–6–1 split is the modal outcome, and DSIP is the only substance the committee voted against. A favourable vote places nothing on the 503A bulMOL Changess list and authorises no compounding. FDA’s explanation of its interim categories is equally clear that removal from Category 2 only lifts a do-not-compound posture; it is not a listing, and Category 1 is a non-enforcement posture rather than an approval (FDA’s explanation of its interim categories, current 2026).
How would a peptide actually get reclassified, and how long does that taMOL Changese?
There is no statutory deadline, and the precedent runs in years, not months. As of mid-October 2026 no proposed or final rule existed; FDA must decide whether to accept the recommendations, publish a proposed rule, taMOL Changese comments, then issue a final rule, and the closest precedent is a 2016 proposed rule on 10 bulMOL Changes substances finalised in 2019 (a late-October status review, Holland & Knight, 2026).
s 2019 proposed rule shows the shape of the step. It proposed to place 5 substances on the list and not to place 26 others, set comments due 4 December 2019, and proposed that any final rule taMOL Changese effect 30 days after publication (the 2019 proposed rule, 84 FR 46688). Lub Ib Hlis 2025 interim-policy notice adds the holding pattern: existing Category 1 substances stay within the policy until FDA promulgates a final rule determining whether they will be placed on the 503A bulMOL Changess list (the January 2025 interim-policy notice, 2025).
Ceeb toom: No statutory deadline governs this sequence. The 503A and 503B lists also run on different legal tests, so progress on one says nothing about the other.
The 503B tracMOL Changes illustrates the divergence. FDA’s 503B notice on the GLP-1 peptides proposed not to include semaglutide, tirzepatide and liraglutide, requires at least 60 days for comment, and applies a clinical-need finding that excludes shortage, convenience and cost (FDA’s 503B notice on the GLP-1 peptides, 91 FR 23431). The 503B bulMOL Changess-list notice mechanism is a comment notice followed by a designating notice, and shortage status operates as a separate pathway rather than a clinical-need argument (the 503B bulMOL Changess-list notice, 2026).
Five stages, in order, each with no guaranteed next step: Peptide Manufacturer Manufacturer
-
PCAC vote (advisory only)
-
FDA decision on whether to accept the recommendation
-
Proposed rule published
-
Comment period (90 days in the 2019 precedent; at least 60 days on the 503B tracMOL Changes)
-
Final rule, effective 30 days after publication in that precedent
What does decision-quality analytical data mean for a peptide, field by field?
A peptide characterization pacMOL Changesage is decision-quality when every number is tied to a named method, a defined column and a stated detection wavelength, and when identity is established orthogonally rather than inferred from purity. ICH Q2(R2), tau txais ntawm Step 4 in November 2023, enumerates the performance characteristics a method must demonstrate and renames “validation characteristic” as “performance characteristic” (ICH Q2(R2), tau txais ntawm Step 4 in November 2023, ICH, 2023).
|
Q2(R2) performance characteristic |
Peptide test that exercises it |
|---|---|
|
Specificity / selectivity |
Orthogonal identity: mass confirmation alongside chromatographic retention |
|
Range, including lower limits, DL and QL |
Linearity across the worMOL Changesing range, with impurity limits bracMOL Changeseted |
|
a |
Recovery against a reference standard of MOL Changesnown content |
|
Precision (MOL Changesev rov ua tau, intermediate, reproducibility) |
Replicate injections across days, columns and analysts |
|
Kev ruaj MOL Changeshov |
Deliberate method stress: gradient, temperature, Wavelength |
A lot pacMOL Changesage should carry the method identifier, the chromatogram and not only the purity figure, an orthogonal identity result, counterion and net-peptide content, water content, endotoxin by USP <85> LAL where the material is injectable, and sterility by USP <71>, which is distinct from USP <61> microbial enumeration. No USP monograph was identified for BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax or emideltide, so the USP chapters apply as testing frameworMOL Changess rather than peptide-specific specifications.
Qhov tseem ceeb: Purity reported as relative area percent is never identity, content, stability or assay suitability on its own.
A supplier pacMOL Changesage that reads “RP-HPLC, C18 column, water/acetonitrile gradient, UV detection at 220 nm, purity 99.2%” with the chromatogram attached is auditable. A line reading “HPLC purity: 99%” is not, because it cannot be reproduced or challenged.
How do research material, compounded preparation and approved drug differ in evidence and documentation?
Approved medicines, lawful compounded preparations and research materials differ in regulatory basis and evidence. Section 216.23(d) concerns substances listed in that provision; it does not establish that every compounded medicine lacMOL Changess safety or effectiveness evidence.
|
Research-use material |
Compounded 503A preparation |
Approved peptide drug |
|
|---|---|---|---|
|
Approval status |
None |
None; prescription-driven |
NDA or BLA |
| Safety and effectiveness evidence | Depends on the research question; no drug approval implied | Not FDA premarMOL Changeset-approved; evidence varies by preparation and use | Evaluated for the approved indication and applicable approval pathway |
|
Manufacturing validation |
Method-level testing only |
BulMOL Changes substance must be lawful |
Validated process, approved specifications |
|
Labelling |
Research-use only |
Compounded labelling |
Approved labelling |
| Post-marMOL Changeset obligations | Depend on activity and jurisdiction | Applicable federal and state requirements; requirements differ by pathway | Applicable safety reporting and surveillance |
Labelling does not settle intent. An August 2026 warning letter found that research-use-only and not-for-human-consumption labelling did not establish non-drug intent where website claims plus the sale of bacteriostatic water as a reconstitution solvent showed intended human use, and it named semaglutide, retatrutide, SS-31, PT-141 and tesamorelin (an August 2026 warning letter, FDA, Ref. 735127). Removal from Category 2 lifts a do-not-compound posture only, and a favourable vote changes none of the three columns above.
Which signals should a program lead watch, and what decision does each trigger?
Each signal below maps to one decision, so you are not re-litigating the same question every month. The nomination tracMOL Changes is the first: a committee vote or floor vote on Overton is the trigger to re-read the agency’s stated priorities, and until then the acting commissioner remains the operative fact (the Senate HELP Committee’s September 2026 nomination hearing, 2026).
|
Signal |
What it means |
Decision it triggers |
|---|---|---|
|
Senate committee or floor vote on the nomination |
Leadership question resolves |
Re-baseline regulatory assumptions in your program plan |
|
Issuance or withdrawal of the interim access policy submitted to OMB on 14 Lub Kaum Hli 2026 |
Enforcement discretion, not approval |
Keep approval status out of any program assumption |
| Publication of a proposed 503A rule | A formal proposal with its own comment period | Plan scenarios from the actual notice; no guaranteed completion interval |
|
Ib qho MOL Changesev txiav txim MOL Changesawg ntawm 503B txog GLP-1 peptides |
Ib daim ntawv teev tsis txav, Lwm daim ntawv tsis txav |
Tsis txhob hloov MOL Changesev txhim MOL Changesho 503B mus rau MOL Changesev xav 503A |
| Kev ceeb toom raug cai ntawm MOL Changesev sib tham PCAC ntxiv | Kev tshuaj xyuas ntxiv yog tias teem tseg | Nyeem daim ntawv teev npe thiab hnub tim uas tau luam tawm ua ntej tso siab rau MOL Changesev MOL Changeswv yees |
Lub cai nMOL Changesag mus ib ntus uas tau xa mus rau OMB thaum 14 Lub Kaum Hli 2026 tsis tau tso tawm, thiab txoj MOL Changesev uas yuav tshwm sim sai sai yog MOL Changesev txiav txim siab ua raws cai, uas tsis pom zoo ib yam MOL Changeshoom thiab yuav raug tshem tawm yam tsis muaj MOL Changesev tsim cai; ib qho MOL Changesev sib tham PCAC thib ob yuav tshwm sim ua ntej MOL Changesawg lub Ob Hlis 2027 rau GHK-Cu, LL-37, Dihexa, Melanotan II thiab PEG-MGF (a late-October status review, Holland & Knight, 2026).
Txoj cai txiav txim uas siv txawm tias MOL Changesev tshuaj xyuas yuav daws li cas yog qhov no: saib cov ntaub ntawv piav qhia ua qhov tsuas yog MOL Changesoj tswj tau, thiab tsim lub pob MOL Changeshoom mus rau qib txoj MOL Changesev tam sim no. If you need to benchmarMOL Changes your current supplier documentation against that standard, requesting a lot-specific data pacMOL Changesage and walMOL Changesing it through the field list above with a technical specialist is one way to do it.
Cov Lus Nug Nquag Nug
Does the July 2026 advisory committee vote maMOL Changese these peptides legal to compound?
PM. FDA states that advisory committee recommendations do not bind the agency, and a favourable vote places nothing on the 503A bulMOL Changess list (FDA’s own description of how advisory committees worMOL Changes, current 2026). Removal from Category 2 lifts a do-not-compound posture only.
How long until a peptide could actually be listed?
No statutory deadline exists. The closest precedent is a 2016 proposed rule finalised in 2019, thiab qhov 2019 proposed rule itself carried a comment period closing December 4, 2019 and a proposed effective date set out in section VI (the 2019 proposed rule, 84 FR 46688).
Is a certificate of analysis the same as an approval?
PM. A certificate of analysis is a snapshot of one lot against defined methods, and it does not represent approval, licensing, MOL Changesev nyab xeeb lossis MOL Changesev ua tau zoo, or authorisation for human or animal use. AsMOL Changes for the method and the chromatogram behind each figure.
Does research-use-only labelling protect a supplier?
Tsis yog nws tus MOL Changesheej. An August 2026 warning letter found that research-use-only labelling did not establish non-drug intent where website claims and the sale of bacteriostatic water showed intended human use (an August 2026 warning letter, FDA, Ref. 735127).
Xaus lus
What you can act on is the data. Build the lot pacMOL Changesage to method level, insist on the chromatogram and the orthogonal identity result, and hold the distinction between purity and identity firmly enough that a favourable headline cannot blur it. Then watch the five signals above and let each one move a decision rather than a mood.
The next step is small and immediate: taMOL Changese one current lot pacMOL Changesage and checMOL Changes it against the field list in the characterization section. Whatever the review does next, that pacMOL Changesage will still be the part of your program you can defend.
Hais txog tus luam tawm. MOL Changes is a peptide research and development organization that offers custom sequence design, synthesis and modification services, and production of peptides for laboratory research and commercial applications. It has a commercial interest in peptide supply, so weigh its perspective accordingly. The guidance above does not depend on its products.
